SecBot SecBot
425 ·Filed Nov 9, 2026

HOWL

Werewolf Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6d 19h ago SEC0001140361-26-042855
Rule 425 M&A communications
Actionable Insight • Neutral

The merger is on track for Q4 2026 close; the key catalyst is the CRPS-RISE topline data readout expected in 2028. Watch for shareholder vote and any regulatory updates on the interim analysis design.

DirectionNeutral
Confidencehigh
Horizonweeks

neridronate

● Neutral Named in this 425
Impact
Phase
Phase 3
Time to market
Topline Phase 3 results expected in 2028, NDA submission thereafter, potential FDA approval likely no earlier than 2029 if the trial succeeds.
Next catalyst
None dated

What to watchWatch for the timing and outcome of the CRPS-RISE interim analysis, which could allow the trial to stop early for efficacy or futility. The merger with Ambros is still being finalized (S-4/A filed November 10, 2026), and current HOWL shareholders face massive dilution, owning roughly 7% of the combined entity. The $150 million PIPE is expected to fund the company through topline results in 2028 and into 2029, reducing near-term financing risk.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$0.9700
T+0 close · Nov 9, 2026 · via day close
Latest settled
+1.95%
T+1 · $0.9889 · next T+5 in 6h
Vs SPY
+0.63%
α at T+1
Latest observation
+8.93%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $0.9700entry
  2. T+1 · 6d ago +1.95%α +0.63% · $0.9889
  3. T+4 · todayOpen
  4. T+5 · in 6h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ambros Therapeutics presented an Analyst Day deck detailing its pending reverse merger with Werewolf Therapeutics (HOWL), including a concurrent $150M PIPE co-led by RA Capital Management and Janus Henderson Investors. The combined company is valued at ~$697.5M pro forma, with Ambros implied at $500M and Werewolf at $47.5M. The deal is expected to close in Q4 2026, and the combined entity will trade as 'AMBX' with proceeds funding the CRPS-RISE pivotal trial of neridronate through NDA submission.

Key Financial Metrics

Deal Value
$697.5M
Deal Type
merger

Key Facts

  • Reverse triangular merger of Werewolf subsidiary into Ambros; Ambros survives as wholly owned subsidiary.
  • Pro forma combined company value at closing: ~$697.5M.
  • Implied valuation for Ambros: $500M (before concurrent PIPE).
  • Implied valuation for Werewolf: $47.5M ($30M net cash + $17.5M Nasdaq listing value).
  • Concurrent PIPE financing: $150M, co-led by RA Capital Management and Janus Henderson Investors.
  • Pro forma ownership: ~72.0% Ambros, ~6.4% Werewolf, ~21.6% PIPE investors.
  • Post-closing ticker: AMBX on Nasdaq.
  • Proceeds to fund CRPS-RISE pivotal trial, regulatory activities through NDA submission, and pre-commercial activities.
  • Expected close: Q4 2026.
  • Neridronate is a bisphosphonate approved in Italy for CRPS; FDA granted Breakthrough Therapy, Fast Track, and Orphan Drug Designations.
  • Pivotal Phase 3 CRPS-RISE trial (NCT07210515) is recruiting, targeting ~270 patients with primary endpoint at Week 12.
  • FDA agreed to include an interim analysis with group sequential design; trial could stop early for efficacy.
  • Ambros had ~$103.2M in cash, cash equivalents, and short-term investments as of June 30, 2026 (unaudited).
  • Abiogen Pharma holds >5% of Ambros post-merger; Ambros pays transfer price (COGS + low double-digit markup) and mid-single-digit royalty on net sales.

Financial Impact

Combined pro forma enterprise value ~$697.5M; $150M PIPE; Werewolf legacy holders get ~6.4% of combined entity; Ambros valued at $500M.

enterprise valueownershipcash position

Risk Factors

  • Merger requires stockholder approval and other closing conditions; risk of delay or failure to close.
  • CRPS-RISE trial may not meet its primary endpoint; interim analysis may not stop early for efficacy.
  • FDA may require additional clinical data beyond the single Phase 3 study for NDA approval.
  • Neridronate faces potential competition from other bisphosphonates and existing pain management therapies.
  • Reliance on Abiogen for manufacturing and supply; any disruption could delay development.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001140361-26-042855
Document: 0001140361-26-042855-index-headers.html0001140361-26-042855
Document: 0001140361-26-042855-index.html0001140361-26-042855
Document: 0001140361-26-042855.txt0001140361-26-042855

Track record

31 reports on HOWL

Performance horizon

12 of 16 bullish or bearish reports moved the stock their way by T+5. Best: +51.32% at T+60 after the Apr 27, 2026 report. 13 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.9500 Now $0.9910 +4.32% settles Nov 23
  2. Nov 13, 20264d ago EFFECT Neutral 4/10 Entry $0.9803 Now $0.9910 +1.09% settles Nov 20
  3. Nov 10, 20266d ago S-4/A Neutral 5/10 Entry $0.9889 Now $0.9910 +0.21% settles Nov 18
  4. Nov 9, 20267d ago 425 Neutral 5/10 Viewing Entry $0.9700 Now $0.9910 +2.16% settles Nov 17
  5. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
  6. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
  7. Oct 26, 202621d ago S-4/A Bearish 5/10 Entry $1.04 to $1.07 Now $0.9910 +4.71% ▼ −2.88% −4.87% vs SPY
  8. Sep 22, 20267w ago S-4 Bearish 7/10 Entry $0.9894 to $0.9223 Now $0.9910 −0.16% ▲ +6.78% +6.11% vs SPY
  9. Sep 21, 20268w ago SC 13G Neutral 3/10 Entry $0.9800 to $0.9300 Now $0.9910 +1.12% ▼ −5.10% −4.08% vs SPY
  10. Aug 21, 202612w ago 425 Bullish 7/10 Entry $0.8740 to $0.9433 Now $0.9910 +13.39% ▲ +7.93% +7.46% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens in 8h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026